$GH News

Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $190

Canaccord Genuity Maintains Buy on Guardant Health, Raises Price Target to $205

Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $175

Citigroup Maintains Buy on Guardant Health, Raises Price Target to $215

Evercore ISI Group Maintains Outperform on Guardant Health, Raises Price Target to $200

Guardant Health: Great Execution, But At An Excessive Premium

B of A Securities Maintains Buy on Guardant Health, Raises Price Target to $190

Bernstein Maintains Outperform on Guardant Health, Raises Price Target to $200

BTIG Maintains Buy on Guardant Health, Raises Price Target to $190

Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $160

Bernstein Reinstates Outperform on Guardant Health, Announces $175 Price Target

Barclays Maintains Overweight on Guardant Health, Raises Price Target to $150

Guardant Health Inc. (NASDAQ:GH) Shines as a Top Minervini Trend Template and High Growth Momentum Pick

RBC Capital Initiates Coverage On Guardant Health with Outperform Rating, Announces Price Target of $185

Guardant Health Says FDA Approves Guardant360 CDx As Companion Diagnostic For Boehringer Ingelheim's HERNEXEOS

Mizuho Maintains Outperform on Guardant Health, Raises Price Target to $175

Guardant Health, Inc. (GH) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow

Goldman Sachs Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $165

Wolfe Research Assumes Guardant Health at Outperform, Announces Price Target of $150

Evercore ISI Group Upgrades Guardant Health to Outperform, Raises Price Target to $160